Motesanib plus Carboplatin/Paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
dc.contributor.author | Novello, S | |
dc.contributor.author | Scagliotti, G | |
dc.contributor.author | Sydorenko, O | |
dc.contributor.author | Vynnychenko, I | |
dc.contributor.author | Volovat, C | |
dc.contributor.author | Schneider, C | |
dc.contributor.author | Blackhall, Fiona H | |
dc.contributor.author | McCoy, S | |
dc.contributor.author | Hei, Y | |
dc.contributor.author | Spigel, D | |
dc.date.accessioned | 2014-09-22T09:02:28Z | |
dc.date.available | 2014-09-22T09:02:28Z | |
dc.date.issued | 2014-08 | |
dc.identifier.citation | Motesanib plus Carboplatin/Paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. 2014, 9 (8):1154-61 J Thorac Oncol | en |
dc.identifier.issn | 1556-1380 | |
dc.identifier.pmid | 25157768 | |
dc.identifier.doi | 10.1097/JTO.0000000000000227 | |
dc.identifier.uri | http://hdl.handle.net/10541/326331 | |
dc.description.abstract | The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). Treatment and enrollment of patients with squamous histology were permanently discontinued following higher early mortality and gross hemoptysis in those with squamous NSCLC who received motesanib. Enrollment of patients with nonsquamous histology was temporarily halted, but resumed following a protocol amendment (Scagliotti et al. J Clin Oncol. 2012;30:2829-2836). Herein, we report data from the squamous cohort. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | en |
dc.title | Motesanib plus Carboplatin/Paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. | en |
dc.type | Article | en |
dc.contributor.department | *Department of Oncology, University of Turin, San Luigi Hospital, Turin, Italy; †Thoracic Surgery Department, Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine; ‡Sumy Regional Oncology Centre, Sumy State University, Sumy, Ukraine; §Centrul de Oncologie Medicala, Iasi, Romania; ‖Central Hospital Bad Berka, Bad Berka, Germany; ¶Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; #Department of Biostatistics & Epidemiology, Amgen Inc., South San Francisco; **Department of Oncology, Amgen Inc., Thousand Oaks, CA; and ††Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN. | en |
dc.identifier.journal | Journal of Thoracic Oncology | en |
html.description.abstract | The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). Treatment and enrollment of patients with squamous histology were permanently discontinued following higher early mortality and gross hemoptysis in those with squamous NSCLC who received motesanib. Enrollment of patients with nonsquamous histology was temporarily halted, but resumed following a protocol amendment (Scagliotti et al. J Clin Oncol. 2012;30:2829-2836). Herein, we report data from the squamous cohort. |